4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kontafarma China Holdings Limited (1312) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Wan Chai, Hong Kong with about 625 employees. Its market capitalization is roughly HK$184 million. In the fiscal year ended 2025-12-31, 1312 reported HK$915M in revenue and (HK$428M) in net income.
Kontafarma China Holdings Limited, an investment holding company, manufactures and sells chemical drugs, active pharmaceutical ingredients (API), and API intermediates in Mainland China, Singapore, Taiwan, and internationally. The company operates through Pharmaceutical Business and Fitness Business segments.
Interactive charts & full statements → Open the 1312 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | HK$915M | HK$898M | HK$809M | HK$894M | — |
| Gross Profit | HK$514M | HK$516M | HK$471M | HK$506M | — |
| Operating Income (EBIT) | (HK$232M) | (HK$47M) | (HK$136M) | (HK$97M) | — |
| Net Income | (HK$428M) | (HK$76M) | (HK$29M) | (HK$42M) | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | HK$1.1B | HK$1.6B | HK$1.7B | HK$2.1B | — |
| Total Liabilities | HK$589M | HK$626M | HK$665M | HK$964M | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1312 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms